Brokerages Set RxSight, Inc. (NASDAQ:RXST) PT at $61.63

RxSight, Inc. (NASDAQ:RXST) has been given an average rating of “Buy” by the eight analysts that are currently covering the stock, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $61.63.

A number of equities research analysts recently weighed in on the company. Stifel Nicolaus dropped their price target on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Wells Fargo & Company cut their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Oppenheimer reduced their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and issued a $66.00 price target on shares of RxSight in a report on Friday, September 13th. Finally, Jefferies Financial Group started coverage on RxSight in a report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price objective for the company.

RxSight Stock Up 1.0 %

NASDAQ:RXST opened at $46.88 on Wednesday. RxSight has a 12-month low of $28.88 and a 12-month high of $66.54. The stock’s 50 day moving average price is $48.58 and its two-hundred day moving average price is $52.26. The firm has a market capitalization of $1.89 billion, a price-to-earnings ratio of -56.48 and a beta of 1.19.

Insiders Place Their Bets

In other news, Director Shweta Maniar sold 3,782 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total transaction of $173,518.16. Following the sale, the director now directly owns 10,902 shares of the company’s stock, valued at approximately $500,183.76. This represents a 25.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Ilya Goldshleger sold 1,330 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $46.13, for a total value of $61,352.90. Following the completion of the transaction, the insider now owns 42,246 shares in the company, valued at $1,948,807.98. The trade was a 3.05 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 62,702 shares of company stock worth $3,059,197 in the last quarter. 9.36% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On RxSight

Several institutional investors and hedge funds have recently bought and sold shares of the company. Arete Wealth Advisors LLC acquired a new position in shares of RxSight in the 3rd quarter valued at approximately $215,000. Geode Capital Management LLC increased its stake in RxSight by 17.7% in the third quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock valued at $40,398,000 after acquiring an additional 122,775 shares during the last quarter. Barclays PLC increased its stake in RxSight by 389.8% in the third quarter. Barclays PLC now owns 58,786 shares of the company’s stock valued at $2,906,000 after acquiring an additional 46,783 shares during the last quarter. MML Investors Services LLC acquired a new position in RxSight during the third quarter valued at approximately $452,000. Finally, MCIA Inc lifted its stake in RxSight by 5.7% during the third quarter. MCIA Inc now owns 8,459 shares of the company’s stock worth $385,000 after purchasing an additional 459 shares during the last quarter. Institutional investors own 78.78% of the company’s stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.